Michael J Grusby from Buckeye, AZ, age 64

Us Patents

Methods And Compositions For Modulating T Helper (Th) Cell Development And Function
view source
US Patent:

7314623, Jan 1, 2008
Filed:

Jul 15, 2003
Appl. No.:

10/620169
Inventors:

Michael J. Grusby - Newton MA, US
Andrea Wurster - Arlington MA, US
Deborah Young - Melrose MA, US
Mary Collins - Natick MA, US
Matthew Whitters - Hudson MA, US
Assignee:

Wyeth - Madison NJ
International Classification:

A61K 39/00
A61K 39/395
A61K 38/17
US Classification:

4241851, 4241431, 4241551, 514 2, 514 12
Abstract:

Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e. g. , human IL-21, activity or level.

Methods And Compositions For Modulating T Helper (T) Cell Development And Function
view source
US Patent:

7731946, Jun 8, 2010
Filed:

Nov 12, 2007
Appl. No.:

11/938618
Inventors:

Michael J. Grusby - Newton MA, US
Andrea Wurster - Arlington MA, US
Deborah Young - Melrose MA, US
Mary Collins - Natick MA, US
Matthew Whitters - Hudson MA, US
Assignee:

Wyeth LLC - Madison NJ
The President and Fellows of Harvard College - Cambridge MA
International Classification:

A61K 38/20
A61K 38/17
C07K 14/47
US Classification:

424 852, 424 851, 514 12, 514 2, 530351
Abstract:

Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e. g. , human IL-21, activity or level.

Methods For Treating And Preventing Fibrosis
view source
US Patent:

7910105, Mar 22, 2011
Filed:

Apr 13, 2006
Appl. No.:

11/402885
Inventors:

Deborah A. Young - Melrose MA, US
Thomas A. Wynn - Silver Spring MD, US
Mary Collins - Natick MA, US
Michael J. Grusby - Newton MA, US
Assignee:

Wyeth LLC - Madison NJ
The United States of America as represented by the Department of Health and Human Services - Washington DC
President and Fellows of Harvard College - Cambridge MA
International Classification:

A61K 39/395
A61K 38/20
US Classification:

4241451, 514 12
Abstract:

The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e. g. , the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e. g. , the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i. e. , the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e. g. , the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R).

Il-21 Receptor Knockout Animal And Methods Of Use Thereof
view source
US Patent:

20040016010, Jan 22, 2004
Filed:

Apr 17, 2003
Appl. No.:

10/418450
Inventors:

Marion Kasaian - Cambridge MA, US
Matthew Whitters - Hudson MA, US
Andrea Wurster - Arlington MA, US
Mary Collins - Natick MA, US
Deborah Young - Melrose MA, US
Michael Grusby - Newton MA, US
International Classification:

A01K067/027
US Classification:

800/018000
Abstract:

A transgenic non-human mammal with a disruption in its IL-21 receptor gene is provided, along with methods of using the transgenic non-human mammal.

Slim Compositions And Methods Of Use Thereof
view source
US Patent:

20060246543, Nov 2, 2006
Filed:

Mar 3, 2006
Appl. No.:

11/368166
Inventors:

Michael Grusby - Newton MA, US
Takashi Tanaka - Kanagawa, JP
Assignee:

President and Fellows of Harvard College - Cambridge MA
International Classification:

A61K 38/17
C07K 14/47
C07H 21/04
C12P 21/06
US Classification:

435069100, 435320100, 435325000, 514012000, 530350000, 536023500
Abstract:

This invention is based, at least in part, on the discovery of a novel nuclear protein which contains both PDZ and LIM domains, SLIM (STAT-interacting LIM). SLIM interacts with activated STAT molecules. The invention also provides methods of using these novel SLIM compositions. The invention also provides therapeutic methods involving the SLIM nucleic acid and protein molecules of the invention.

Il-21 Receptor Knockout Animal And Methods Of Use Thereof
view source
US Patent:

20100223685, Sep 2, 2010
Filed:

Jan 6, 2010
Appl. No.:

12/683117
Inventors:

Marion KASAIAN - Charlestown MA, US
Matthew WHITTERS - Hudson MA, US
Andrea WURSTER - Arlington MA, US
Mary COLLINS - Natick MA, US
Deborah YOUNG - Melrose MA, US
Michael GRUSBY - Newton MA, US
International Classification:

A01K 67/00
C12Q 1/68
C12N 5/10
C12N 15/63
US Classification:

800 14, 435 6, 435354, 800 18, 800 22, 800 25
Abstract:

A transgenic non-human mammal with a disruption in its IL-21 receptor gene is provided, along with methods of using the transgenic non-human mammal.

Methods For Treating And Preventing Fibrosis
view source
US Patent:

20110142833, Jun 16, 2011
Filed:

Feb 18, 2011
Appl. No.:

13/030840
Inventors:

Deborah A. YOUNG - Melrose MA, US
Thomas A. Wynn - Silver Spring MD, US
Mary Collins - Natick MA, US
Michael J. Grusby - Newton MA, US
International Classification:

A61K 38/17
A61K 39/395
A61P 11/00
A61P 1/16
A61P 17/00
A61P 29/00
C12Q 1/02
US Classification:

4241331, 514 212, 514 186, 4241411, 514 205, 424649, 435 29
Abstract:

The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e.g., the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i.e., the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e.g., the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R).

Stat6 Deficient Transgenic Mice
view source
US Patent:

58667601, Feb 2, 1999
Filed:

Mar 21, 1997
Appl. No.:

8/823051
Inventors:

Michael J. Grusby - Boston MA
Mark H. Kaplan - Boston MA
Assignee:

President and Fellows of Harvard College - Cambridge MA
International Classification:

C12N 500
C12N 1500
C12N 1509
US Classification:

800 18
Abstract:

The invention provides methods and compositions for evaluating modulators of the Stat6 signaling pathway; in a particular, transgenic mice comprising a transgene within a Stat6 allele locus, encoding a selectable marker and displacing the SH2-encoding domain of the Stat6 allele. More particularly, the transgene may comprise 3' and 5' regions with sufficient complementarity to the natural Stat6 allele at the locus to effect homologous recombination of the transgene with the Stat6 allele. Such mice provide useful animal models for determining the effect of candidate drugs on a host deficient in Stat6 function. The invention provides a variety of methods for making and using the subject compositions; in particular, methods for determining the effect of a candidate drug on a mouse deficient in Stat6 function and methods of evaluating the side effects of a Stat6 function inhibitor.